Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 12/20 | 0.57 |
| ▸ | SLC16A3 | O15427 | 4/20 | 0.41 |
| ▸ | SLC16A1 | P53985 | 4/20 | 0.41 |
| ▸ | MCTS1 | Q9ULC4 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111013 | 0.91 | PPARG (0.53) | PPARGSLC16A3SLC16A1MCTS1 | |
| SCHEMBL5110607 | 0.88 | PPARG (0.74) | PPARG | |
| SCHEMBL5114784 | 0.87 | PPARG (0.47) | PPARGGAA | |
| SCHEMBL5120100 | 0.86 | PPARG (0.50) | PPARGSMN1; SMN2MEN1KMT2A | |
| SCHEMBL5112535 | 0.86 | PPARG (0.59) | PPARGMEN1KMT2A | |
| SCHEMBL5113441 | 0.85 | PPARG (0.54) | PPARGSLC16A3SLC16A1MCTS1MEN1 | |
| SCHEMBL5109249 | 0.83 | PPARG (0.63) | PPARG | |
| SCHEMBL5119385 | 0.83 | PPARG (0.46) | PPARGMEN1KMT2A | |
| SCHEMBL5113716 | 0.82 | PPARG (0.60) | PPARG | |
| SCHEMBL5114920 | 0.82 | PPARG (0.60) | PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-02-28 | — | — | US | disclosed |
| EP-1829863-A1 | ARYLALKANOIC ACID DERIVATIVE | Takeda Pharmaceutical Company Limited (JP) | 2007-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051418-A1 | Arylalkanoic Acid Derivative | INSR, NPY1R, GPR119 | PPARG 52/4885SLC16A3 1212/4885SLC16A1 1878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.